Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.

Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD.

Anticancer Drugs. 2008 Jan;19(1):77-84.

PMID:
18043132
2.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

3.

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81.

4.

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE.

Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16.

5.

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS.

J Clin Oncol. 2006 Sep 1;24(25):4092-9.

PMID:
16943527
6.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ.

Ann Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.

PMID:
15939714
7.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.

J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13.

8.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L.

J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20.

PMID:
20855840
9.

Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.

Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC.

Clin Cancer Res. 2005 Aug 15;11(16):5942-9.

10.

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.

Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK.

Ann Oncol. 2001 May;12(5):605-14.

PMID:
11432617
11.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT.

J Clin Oncol. 2005 Feb 1;23(4):889-98.

PMID:
15681535
12.

Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.

Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ.

Am J Clin Oncol. 2008 Feb;31(1):1-5. doi: 10.1097/COC.0b013e31805c142f.

PMID:
18376220
13.

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC.

Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.

PMID:
20092990
14.

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

Chu QS, Schwartz G, de Bono J, Smith DA, Koch KM, Versola MJ, Pandite L, Arya N, Curtright J, Fleming RA, Ho PT, Rowinsky EK.

J Clin Oncol. 2007 Aug 20;25(24):3753-8.

PMID:
17704424
15.

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.

Clemons M, Joy AA, Abdulnabi R, Kotliar M, Lynch J, Jordaan JP, Iscoe N, Gelmon K.

Breast Cancer Res Treat. 2010 Nov;124(1):177-86. doi: 10.1007/s10549-010-1152-0. Epub 2010 Sep 3.

PMID:
20814815
16.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC.

Cancer Chemother Pharmacol. 2005 Apr;55(4):354-60. Epub 2004 Oct 27.

PMID:
15723261
17.

A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.

Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M.

Cancer Chemother Pharmacol. 2010 Apr;65(5):863-9. doi: 10.1007/s00280-009-1091-9. Epub 2009 Aug 6.

18.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1149-55. doi: 10.1007/s00280-009-0977-x. Epub 2009 Mar 26.

19.

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.

Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, Spigel DR, Hainsworth JD, Burris HA 3rd.

Cancer Chemother Pharmacol. 2012 Jan;69(1):137-44. doi: 10.1007/s00280-011-1674-0. Epub 2011 May 28.

PMID:
21626051
20.

A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.

Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT.

Clin Cancer Res. 1998 Nov;4(11):2755-61.

Supplemental Content

Support Center